379 related articles for article (PubMed ID: 21447800)
1. c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance.
Pyndiah S; Tanida S; Ahmed KM; Cassimere EK; Choe C; Sakamuro D
Sci Signal; 2011 Mar; 4(166):ra19. PubMed ID: 21447800
[TBL] [Abstract][Full Text] [Related]
2. MYC, PARP1, and chemoresistance: BIN there, done that?
Ganesan S
Sci Signal; 2011 Mar; 4(166):pe15. PubMed ID: 21447796
[TBL] [Abstract][Full Text] [Related]
3. [c-MYC, PARP1 and BIN1 as targets for therapy of cancer cell resistance].
Pyndiah S; Sakamuro D
Med Sci (Paris); 2013 Feb; 29(2):133-5. PubMed ID: 23452595
[No Abstract] [Full Text] [Related]
4. Regulation of E2F1-induced apoptosis by poly(ADP-ribosyl)ation.
Kumari A; Iwasaki T; Pyndiah S; Cassimere EK; Palani CD; Sakamuro D
Cell Death Differ; 2015 Feb; 22(2):311-22. PubMed ID: 25257171
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus E1A oncoprotein liberates c-Myc activity to promote cell proliferation through abating Bin1 expression via an Rb/E2F1-dependent mechanism.
Kinney EL; Tanida S; Rodrigue AA; Johnson JK; Tompkins VS; Sakamuro D
J Cell Physiol; 2008 Sep; 216(3):621-31. PubMed ID: 18348166
[TBL] [Abstract][Full Text] [Related]
6. New Synthetic Lethality Re-Sensitizing Platinum-Refractory Cancer Cells to Cisplatin In Vitro: The Rationale to Co-Use PARP and ATM Inhibitors.
Folk WP; Kumari A; Iwasaki T; Cassimere EK; Pyndiah S; Martin E; Homlar K; Sakamuro D
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948122
[TBL] [Abstract][Full Text] [Related]
7. Loss of the tumor suppressor BIN1 enables ATM Ser/Thr kinase activation by the nuclear protein E2F1 and renders cancer cells resistant to cisplatin.
Folk WP; Kumari A; Iwasaki T; Pyndiah S; Johnson JC; Cassimere EK; Abdulovic-Cui AL; Sakamuro D
J Biol Chem; 2019 Apr; 294(14):5700-5719. PubMed ID: 30733337
[TBL] [Abstract][Full Text] [Related]
8. The c-MYC-interacting proapoptotic tumor suppressor BIN1 is a transcriptional target for E2F1 in response to DNA damage.
Cassimere EK; Pyndiah S; Sakamuro D
Cell Death Differ; 2009 Dec; 16(12):1641-53. PubMed ID: 19629135
[TBL] [Abstract][Full Text] [Related]
9. Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms.
Elliott K; Sakamuro D; Basu A; Du W; Wunner W; Staller P; Gaubatz S; Zhang H; Prochownik E; Eilers M; Prendergast GC
Oncogene; 1999 Jun; 18(24):3564-73. PubMed ID: 10380878
[TBL] [Abstract][Full Text] [Related]
10. c-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-kappa B activity in pancreatic cancer cells.
Biliran H; Banerjee S; Thakur A; Sarkar FH; Bollig A; Ahmed F; Wu J; Sun Y; Liao JD
Clin Cancer Res; 2007 May; 13(9):2811-21. PubMed ID: 17473215
[TBL] [Abstract][Full Text] [Related]
11. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
[TBL] [Abstract][Full Text] [Related]
12. The c-Myc-interacting adaptor protein Bin1 activates a caspase-independent cell death program.
Elliott K; Ge K; Du W; Prendergast GC
Oncogene; 2000 Sep; 19(41):4669-84. PubMed ID: 11032017
[TBL] [Abstract][Full Text] [Related]
13. Replication fork stability confers chemoresistance in BRCA-deficient cells.
Ray Chaudhuri A; Callen E; Ding X; Gogola E; Duarte AA; Lee JE; Wong N; Lafarga V; Calvo JA; Panzarino NJ; John S; Day A; Crespo AV; Shen B; Starnes LM; de Ruiter JR; Daniel JA; Konstantinopoulos PA; Cortez D; Cantor SB; Fernandez-Capetillo O; Ge K; Jonkers J; Rottenberg S; Sharan SK; Nussenzweig A
Nature; 2016 Jul; 535(7612):382-7. PubMed ID: 27443740
[TBL] [Abstract][Full Text] [Related]
14. MCL-1 dependency of cisplatin-resistant cancer cells.
Michels J; Obrist F; Vitale I; Lissa D; Garcia P; Behnam-Motlagh P; Kohno K; Wu GS; Brenner C; Castedo M; Kroemer G
Biochem Pharmacol; 2014 Nov; 92(1):55-61. PubMed ID: 25107702
[TBL] [Abstract][Full Text] [Related]
15. c-Myc down-regulation increases susceptibility to cisplatin through reactive oxygen species-mediated apoptosis in M14 human melanoma cells.
Biroccio A; Benassi B; Amodei S; Gabellini C; Del Bufalo D; Zupi G
Mol Pharmacol; 2001 Jul; 60(1):174-82. PubMed ID: 11408612
[TBL] [Abstract][Full Text] [Related]
16. A structure-based model of the c-Myc/Bin1 protein interaction shows alternative splicing of Bin1 and c-Myc phosphorylation are key binding determinants.
Pineda-Lucena A; Ho CS; Mao DY; Sheng Y; Laister RC; Muhandiram R; Lu Y; Seet BT; Katz S; Szyperski T; Penn LZ; Arrowsmith CH
J Mol Biol; 2005 Aug; 351(1):182-94. PubMed ID: 15992821
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose) polymerase 1 activation is required for cisplatin nephrotoxicity.
Kim J; Long KE; Tang K; Padanilam BJ
Kidney Int; 2012 Jul; 82(2):193-203. PubMed ID: 22437413
[TBL] [Abstract][Full Text] [Related]
18. c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias.
Muvarak N; Kelley S; Robert C; Baer MR; Perrotti D; Gambacorti-Passerini C; Civin C; Scheibner K; Rassool FV
Mol Cancer Res; 2015 Apr; 13(4):699-712. PubMed ID: 25828893
[TBL] [Abstract][Full Text] [Related]
19. Identification of tyrosine kinase, HCK, and tumor suppressor, BIN1, as potential mediators of AHI-1 oncogene in primary and transformed CTCL cells.
Kennah E; Ringrose A; Zhou LL; Esmailzadeh S; Qian H; Su MW; Zhou Y; Jiang X
Blood; 2009 May; 113(19):4646-55. PubMed ID: 19211505
[TBL] [Abstract][Full Text] [Related]
20. The role of DNA repair pathways in cisplatin resistant lung cancer.
O'Grady S; Finn SP; Cuffe S; Richard DJ; O'Byrne KJ; Barr MP
Cancer Treat Rev; 2014 Dec; 40(10):1161-70. PubMed ID: 25458603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
